Conatus Pharmaceuticals Receives U.S. Orphan Drug Designation for Emricasan for Treatment of Liver
– SAN DIEGO (GLOBE NEWSWIRE) - Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation…